22 December 2013

Introducing The Rowboat
A advanced Covered Call system that is quite possibly The Holy Grail of
Step 1: Sell the Put
( This is a Cash Covered Put, I have to have enough Cash to buy 100 shares per contract if
the option is exercised, this is also my maximum risk. )
QCOR @ $53.26
Questcor Pharmaceuticals, Inc.
Sell To Open QCOR Jan 2014 $50 Put @ Market
Currently $2.90 bid / $3.05 time
5.8% return in 25 days
$ 10,000 should generate $580.00
How to do this trade and commentary Video:
http://youtu.be/CWaMp5-E9Dg
Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs
for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms
indications. It primarily offers H.P. Acthar Gel, an injectable drug for the
treatment of acute exacerbations of multiple sclerosis in adults; to induce a
diuresis or a remission of proteinuria in the nephrotic syndrome without uremia
of the idiopathic type or that due to lupus erythematosus; and as monotherapy
for the treatment of infantile spasms in infants and children under two years of
age. The company s H.P. Acthar Gel also focuses on rheumatology-related
conditions, including collagen diseases and rheumatic disorders. In addition, it
offers Doral for the treatment of insomnia. The company sells its Acthar
primarily to specialty pharmacies; and Doral to pharmaceutical wholesalers.
Questcor Pharmaceuticals, Inc. was founded in 1990 and is headquartered in
Anaheim, California.

Questcor Pharmaceuticals, Inc.

1300 North Kellogg Drive Suite D

Anaheim, CA 92807

Phone: 714-786-4200 Fax: 714-789-4229

Website: http://www.questcor.com

SCTY @ $55.80

solar city corporation

Sell To Open SCTY January 2014 $55.00 Put @ Market

currently $3.60 bid / $3.70 time

6.5% return in 25 days

$10,000 should generate $650.00

How to do this trade and commentary Video:

http://youtu.be/EnsRRhcAW6E

Sign up with a auto-trading company and let your broker do the trades for you.

SolarCity Corporation engages in the design, installation, and sale or lease of solar energy systems to residential and commercial customers, and government entities in the United States. It provides solar energy systems; and energy efficiency products and services, including home energy evaluation, and energy efficiency upgrade products and services. The company also sells electricity generated by solar energy systems to customers. In addition, it markets and installs electric vehicle charging equipment to residential and commercial customers through retail partnerships. The company was founded in 2006 and is headquartered in San Mateo, California.

SolarCity Corporation

3055 Clearview Way

San Mateo, CA 94402

Phone: 650-638-1028

Fax: 650-638-1029

Website: http://www.solarcity.com

News:

How to do this trade and commentary Video:

Sign up with a auto-trading company and let your broker do the trades for you.

http://youtu.be/9CNUO9AV7Cw

Remember, no more than 5 or 10% of your portfolio should ever go into
any one trade or position.

Step 2: IF it got Put to us, Now we “Lock-in” a profit.
Sell the Covered Call
(Do not buy a stock just to sell the covered Call)

MYGN @ $24.00

Myriad Genetics Inc. (MYGN)

Sell To Open MYGN January $27 Call @ Market

currently .85c bid / .95c time
+3.4% return in 25 days

History:

Cost basis $25.00 per share. Premiums collected: $1.90 per share 7.6% Return in 1 months

$10,000 would have generated $760.00

actual trades:

11/18/2013 Sell To Open MYGN Dec13 $25 Put $1.90

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. The company’s molecular diagnostic tests are designed to analyze genes, their mutations, expression levels, and proteins to assess an individuals risk for developing disease later in life; determine a patients likelihood of responding to a particular drug; and assess a patients risk of disease progression and disease recurrence. It offers various molecular diagnostic tests that include BRACAnalysis and BART, which are predictive medicine tests for hereditary breast and ovarian cancer; COLARIS predictive medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; MELARIS predictive medicine test for hereditary melanoma; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized and prognostic medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and TheraGuide 5-FU, a personalized medicine test for drug toxicity. The company, through its subsidiary, Myriad RBM, Inc., also offers biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical research industries that include multi -analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self-contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.

Myriad Genetics Inc.

320 Wakara Way

Salt Lake City, UT 84108 Phone: 801-584-3600 Fax: 801-584-3640

Website: http://www.myriad.com

News: http://finance.yahoo.com/news/myriad-myrisk-hereditary-cancer-tm-230000882.html

VJET @ $36.89

Voxeljet AG (VJET)
Sell To Open VJET Feb 2014 $60 Call @ Market
currently .35c bid / .45c time
+.06% return in 60 days
History:
Cost basis $55.00 per share.
Premiums collected: $4.00 per share
7.2% Return in 1 months
$10,000 would have generated $720.00
actual trades:
11/18/2013 Sell To Open VJET Dec13 $55 Put $4.00
voxeljet AG provides three-dimensional (3D) printers and on-demand parts services. Its 3D
printers employ a powder binding additive manufacturing technology to produce parts using
various material sets. The company operates in two segments, Systems and Services. The
Systems segment focuses on the production, development, and sale of 3D printers. It also
offers consumables, such as particulate materials and proprietary chemical binding agents,
maintenance contracts, and spare parts. The Services segment prints on-demand parts at
its service center through its 3D printers, material sets, and in-house finishing capabilities.
The company provides its 3D printers and on-demand parts services to industrial and
commercial customers in automotive, aerospace, film and entertainment, art and
architecture, engineering, and consumer product end markets in Europe, the Middle East,
Africa, the Asia Pacific, and the Americas. voxeljet AG was founded in 1999 and is
headquartered in Friedberg, Germany
Voxeljet AG
Paul-Lenz Strasse 1b
Friedberg, 86316
Germany
Phone: 49 821 7483 100
Fax: 49 821 7483 111
Website: http://www.voxeljet.de
News: http://seekingalpha.com/article/1907041-3-must-own-3d-printing-stocks?
Remember, no more than 5 or 10% of your portfolio should ever go into
any one trade or position.

How did we do last Month?

Expired Puts

SCTY @ $55.35

solar city corporation

4.81% return

Strategy: Sold Puts

10/21/2013 Sell To Open SCTY Nov13 55 Put $2.65

4.81% return in 25 days

$10,000 would have generated $481.00

Current/Older Positions/History

This includes a running total for each open position.

Do not enter these positions.

CLSN @ $3.92

Celsion Corporation

Put to us @ $2.00

Sell To Open CLSN Jan 2014 $4 Call @ Market

currently .20 bid / .28 time

History:

Cost basis $2.00 per share.

Premiums collected: $.75 per

share 37.5%* Return in 12 months

$10,000 would have generated $2500.00

actual trades:

11/18/2013 Sell To Open CLSN Dec13 $4 Call $0.25
02/19/2013 Sell To Open CLSN July 2013 $3 Call

(did not fill, because of Holiday) 0.00

02/15/2013 Buy CLSN – Option Assignment $2.00 01/22/2013 Sell To Open CLSN Feb13 2 Put $0.30 12/24/2012 Sell To Open CLSN Jan13 2 Put $0.20

Celsion Corporation, an oncology drug development company, engages in the development and commercialization of targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company develops ThermoDox, a liposomal encapsulation of doxorubicin, which is under Phase III clinical trial for primary liver cancer; under phase II clinical trial for colorectal liver metastasis; and under phase II clinical trial for treatment of recurrent chest wall breast cancer. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. for ThermoDox; a license agreement with Duke University to commercialize and use Duke’s thermo-liposome technology; and a joint research agreement with Royal Philips Electronics to evaluate the combination of Philips’ high intensity focused ultrasound with its ThermoDox to determine the potential of this combination to treat various cancers. The company was founded in 1982 and is based in Lawrenceville, New Jersey.

Celsion Corp.

997 Lenox Drive Suite 100

Lawrenceville, NJ 08648

Phone: 609-896-9100

Fax: 609-896-2200

Website: http://www.celsion.com

News: http://seekingalpha.com/article/1897411-celsion-shows-possible-enormous-thermodox-potential-in-phase-i-dignity-results?

* This does not factor in any stock split.

DMND @ $24.49

Put to us @ $32.00

Hold

No good options at this time

6.7% Return

History:

Cost basis $32.00 per share. Premiums collected: 2.15 per share 6.7% Return in 21 months

$10,000 would have generated $670.00

actual trades:

09/24/2012 Sell To Open DMND Dec12 30 Call $0.20 03/20/2012 Sell To Open DMND Jun12 33 Call $0.25 03/18/2012 Buy To Close EXPIRED DMND Mar12 32 CALL 02/21/2012 Sell To Open DMND Mar12 32 Call $0.20 02/17/2012 Buy DMND – Option Assignment $32.00 02/17/2012 Buy To Close DMND Feb12 32 Put 02/06/2012 Sell To Open DMND Feb12 32 Put $1.50

Diamond Foods, Inc. engages in processing, marketing, and distributing snack products. It provides snack products, including roasted, glazed and flavored nuts, trail mixes, dried fruit, seeds, microwave popcorn products, and potato and tortilla chips under the Emerald, Pop Secret, and Kettle brands. The company also offers culinary, in-shell, and ingredient nuts under the Diamond of California brand name. It markets its culinary nuts to individuals who prepare meals or baked goods at home; and ingredient nuts to food processors, restaurants, bakeries, and food service companies and their suppliers. The company sells its products directly to national grocery, mass merchandiser, clubs, convenience stores, and drug store chains in the United States, the United Kingdom, Germany, the Netherlands, Spain, Canada, South Korea, Turkey, China, and Japan. Diamond Foods, Inc. was founded in 1912 and is based in San Francisco, California.

Diamond Foods, Inc.

600 Montgomery Street 13th Floor

San Francisco, CA 94111-2702 Phone: 415-445-7444

Website: http://www.diamondfoods.com

News: http://www.fool.com/investing/general/2013/12/09/inside-diamond-foods-shame-and-3-key-takeaways-fro.aspx#.UrXUHvtyX3g

ONTY @ $1.83

HOLD no good options at this time

History:

Cost basis $5.00 per share.

Premiums collected: 2.20 per share 44% Return in 23 months

$10,000 would have generated $4400.00

actual trades:

03/18/2013 Sell To Open ONTY Jun13 5 Call $0.05
11/19/2012 Sell To Open ONTY Jan13 6 Call $0.55
05/21/2012 Sell To Open ONTY Nov12 7 Call $0.05
03/20/2012 Sell To Open ONTY May12 6 Call $0.05
03/16/2012 Buy ONTY – Option Assignment $5.00
03/16/2012 Buy To Close ONTY Mar12 $5 Put
02/21/2012 Sell To Open ONTY Mar12 $5 Put $0.70
02/19/2012 Buy To Close EXPIRED ONTY FEB12 $5 PUT
01/30/2012 Sell To Open ONTY Feb12 5 Put $0.50
01/22/2012 Buy To Close EXPIRED ONTY JAN12 $5 PUT
01/09/2012 Sell To Open ONTY Jan12 5 Put $0.30

Oncothyreon Inc.(ONTY), a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its primary product candidate, Stimuvax is in Phase III clinical trials for the treatment of non-small cell lung cancer. The company also develops PX- 866, a small molecule that is in Phase II trials. In addition, it engages in the preclinical development of ONT-10, a cancer vaccine. The company operates in Canada, the United States, Barbados, and Europe. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.

Oncothyreon Inc

2601 Fourth Avenue Suite 500

Seattle, WA 98121 Phone: 206-801-2100 Fax: 206-801-2101

Website:http://www.oncothyreon.com

News:

PRKR @ $4.47

Parkervision Inc.

Sell To Open PRKR March 2014 $6 Call @ market

Currently .20c bid / .28c time

History:

Cost basis $5.00 per share.

Premiums collected: $.45 per

share 9% Return in 2 months

$10,000 would have generated $450.00

actual trades:

10/21/2013 Sell To Open PRKR Nov13 5 Put $0.45

Parker Vision, Inc. designs, develops, and markets proprietary radio frequency (RF) technologies and products for use in semiconductor circuits for wireless communication products in the United States. It offers its technologies for processing RF waveforms in wireless applications. Its technology applies to both transmit and receive functions of a radio transceiver. The transmit portion of the technology, Direct2Power, enables the transformation of a baseband data signal to an RF carrier waveform at the desired power output level in a single unified operation. The receiver portion of the technology, Direct2Data, enables the direct conversion of an RF carrier to a baseband data signal. The company also provides engineering consulting and design services to its customers to assist them in developing prototypes and/or products incorporating its technologies. It focuses on incorporating its technologies into mobile handsets for 3G and 4G cellular networks, as well as to other wireless products that are related to networks serving mobile handsets, such as tablets, data cards, femtocells, machine-to-machine, and embedded applications. The company s technology is also used in non-cellular radio applications comprising military radios and cable modems. ParkerVision, Inc. was founded in 1989 and is headquartered in Jacksonville, Florida.

Parkervision Inc.

7915 Bay meadows Way Suite 400

Jacksonville, FL 32256

Phone: 904-732-6100 Fax: 904-731-0958

Website:http://www.parkervision.com

PAAS @ $11.14

Hold

there are no good options at this time.

History:

Cost basis $36.00 per share.

Premiums collected: $3.50 per share

Dividends : .35c

Total: $3.97

11.02% Return in 32 months

$10,000 would have generated $1102.00

actual trades:

09/06/2013 PAAS – PAAS QUALIFIED DIVIDEND .125

06/19/2013 PAAS – PAAS QUALIFIED DIVIDEND .125 03/19/2013 PAAS – PAAS QUALIFIED DIVIDEND .125 12/04/2012 PAAS – PAAS QUALIFIED DIVIDEND .125

09/24/2012 Sell To Open PAAS Jan13 40 Call $0.05
01/30/2012Sell To Open PAAS Jul12 36 Call $0.20
12/06/2011 PAAS – PAAS QUALIFIED DIVIDEND $.025
10/24/2011 Sell To Open PAAS Jan12 36 Call $0.40
10/22/2011 Buy To Close EXPIRED PAAS Oct11 36 Call
09/08/2011 PAAS – PAAS QUALIFIED DIVIDEND $.025
06/20/2011 Sell To Open PAAS Oct11 36 Call $0.80
06/19/2011 Buy To Close EXPIRED PAAS JUN11 36 CALL
06/16/2011 PAAS QUALIFIED DIVIDEND $.025
05/23/2011 Sell To Open PAAS Jun11 36 Call $0.50
05/20/2011 Buy PAAS – Option Assignment $36.00
05/20/2011 Buy To Close PAAS May11 36 Put $0.00
04/18/2011 Sell To Open PAAS May11 36 Put $1.55

Pan American Silver Corp. engages in the exploration, development, extraction, processing, production, refining, reclamation, and operation of silver properties. The company also produces and sells gold, zinc, lead, and copper. As of April 27, 2011, it had seven silver mining operations in Mexico, Peru, Argentina, and Bolivia. The company was founded in 1979 and is headquartered in Vancouver, Canada.

Pan American Silver Corp.

625 Howe Street Suite 1500

Vancouver, BC V6C 2T6 Phone: 604-684-1175 Fax: 604-684-0147

Website: http://www.panamericansilver.com

News:

http://www.fool.com/investing/general/2013/12/10/this-silver-miner-will-be-strong-in-2014.aspx#.UrXWUPtyX3g

PAY @ $24.15

Hold: no good options at this time.

History:

Cost basis $43.00 per share. Premiums collected: $3.36 per share 7.63% Return in 31 months

$10,000 would have generated $758.00

actual trades:

10/22/2012 Sell To Open PAY Jan13 44 Call $0.10

06/18/2012 Sell To Open PAY Oct12 $44 Call $0.35

05/21/2012 Sell To Open PAY Jun12 50 Call $1.00

04/16/2012 Sell To Open PAY May12 57.5 Call $1.02

04/16/2012 Buy To Close PAY Apr12 49 Call -$5.36

01/23/2012 Sell To Open PAY Apr12 49 Call $0.40

01/22/2012 Buy To Close EXPIRED PAY JAN12 49 CALL

10/31/2011 Sell To Open PAY Jan12 49 Call $0.90

10/31/2011 Buy To Close PAY Jan12 46 Call -$1.90

10/24/2011 Sell To Open PAY Jan12 46 Call $1.10

10/22/2011 Buy To Close EXPIRED PAY Oct11 42 Call

08/23/2011 Sell To Open PAY Oct11 42 Call $0.60

08/21/2011 Buy To Close EXPIRED PAY AUG11 46 Call

07/19/2011 Sell To Open PAY Aug11 46 Call $1.05

07/17/2011 Buy To Close EXPIRED PAY JUL11 44 Call

06/20/2011 Sell To Open PAY Jul11 44 Call $0.75

06/17/2011 Buy To Close PAY Jun11 43 Put $0.00

06/17/2011 Buy PAY – Option Assignment $43.00

05/23/2011 Sell To Open PAY Jun11 43 Put $1.70

VeriFone Systems, Inc. designs, markets, and services electronic payment solutions that enable secure electronic payments among consumers, merchants, and financial institutions worldwide. The company provides countertop electronic payment systems that accept magnetic, smart card, and contactless/radio frequency identification cards; and support credit, debit, check, electronic benefits transfer, and various pre-paid products, as well as offers wireless system solutions. The company also provides products for the point of sale applications, which include displays, user-friendly interfaces, electronic cash registers (ECR) interfaces, durable key pads, and signature capture functionality; and contactless/near field communication (NFC) payment solutions for consumer-activated transactions using contactless cards, tokens, or NFC enabled mobile phones. In addition, it offers various products for petroleum companies, such as integrated electronic payment systems that combine card processing, fuel dispensing, and ECR functions, as well as secure payment systems for integration with petroleum pump controllers and systems. Further, the company provides server-based transaction products; secure payment hardware and software integration modules; and VeriShield Protect, a solution that encrypts and protects consumer card data. Additionally, it offers client services, including payment system consulting, deployment, on- site and telephone- based installation and training, help desk support, repairs, replacement of impaired system solutions, asset tracking, and reporting; and project management services. The company serves financial institutions, payment processors, petroleum companies, retailers, government organizations, and healthcare companies, as well as independent sales organizations. The company was formerly known as VeriFone Holdings, Inc. and changed its name to VeriFone Systems, Inc. in May 2010. The company is headquartered in San Jose, California.

VeriFone Systems, Inc

2099 Gateway Place Suite 600

San Jose, CA 95110

Phone: 408-232-7800 Fax: 408-232-7811

Website: http://www.verifone.com

News:

http://www.fool.com/investing/general/2013/12/20/verifone-earnings-key-takeaways-and-what-investors.aspx#.UrXWzPtyX3g

TRGT @ $4.10

Hold

Take no action

There is no good option interest at this time.

History:

Cost basis $12.50 per share.

Premiums collected: $2.25 per share 18% Return in 26 months

$10,000 would have generated $1800.00

actual trades:

02/21/2012 Sell To Open TRGT May12 15 Call $0.25

11/28/2011 Sell To Open TRGT Feb12 15 Call $0.40

11/18/2011 Buy To Close TRGT Nov11 12.5 Put

11/18/2011 Buy TRGT – Option Assignment $12.50 10/23/2011 Sell to Open TRGT Nov 11 $12.50 PUT $1.60

Targacept, Inc., a biopharmaceutical company, engages in the design, discovery, and development of novel Neuronal Nicotinic Receptors (NNR) Therapeutics for the treatment of diseases and disorders of the nervous system. Its lead program, TC-5214, a nicotinic channel modulator, is in Phase 3 clinical trials as an adjunct treatment for major depressive disorder (MDD) and in Phase 2b clinical trial for switch monotherapy in patients with MDD. The company s novel small molecule product candidates under Phase 2 clinical development include TC-5619 for treating negative symptoms and cognitive dysfunction in schizophrenia, attention deficit/hyperactivity disorder, and Alzheimer s disease; AZD3480 as a treatment for mild to moderate Alzheimer s disease; AZD1446 as a treatment for Alzheimer s disease; and TC-6987 for the treatment of inflammatory disorders, including asthma and Type 2 diabetes. It has a collaborative research and license agreement with AstraZeneca AB for the development and commercialization of AZD3480, TC-5214, and TC-5619; and a product development and commercialization agreement with SmithKline Beecham Corporation to discover, develop, and market product candidates that selectively target specified NNR subtypes in specified therapeutic focus areas. The company was founded in 1997 and is based in Winston-Salem, North Carolina.

Targacept, Inc.

200 East First Street Suite 300

Winston-Salem, NC 27101-4165 Phone: 336-480-2100

Fax: 336-480-2107

Website: http://www.targacept.com

News:

Earnings report in February
ZIOP @ $4.00

ZIOPHARM Oncology, Inc.

Hold: January 2014 $5 Call still cooking

History:

Cost basis $3.00 per share. Premiums collected: $.25 per share 8.33% Return in 9 months

$10,000 would have generated $666.00

actual trades:

04/22/2013 Sell To Open ZIOP Jan14 $5 Call $0.05 04/19/2013 Buy ZIOP – Stock Assignment $ 3.00 03/18/2013 Sell To Open ZIOP Apr13 3 Put $0.20

ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of new cancer therapies. Its lead candidate, Palifosfamide (ZIO-201), a potent bi-functional DNA alkylating agent, is under Phase III trial for the treatment of first-line metastatic soft tissue sarcoma, as well as in a pivotal Phase III trial for first -line metastatic small cell lung cancer. The company s portfolio of clinical-stage product candidates also include IL-12 DNA, which is being tested in a Phase 2 study using synthetic biology to enable controlled, local delivery of therapeutic interleukin-12; Indibulin (ZIO-301), a novel, tubulin binding agent under Phase I/II trial in metastatic breast cancer; and Darinaparsin (ZIO-101), a novel mitochondrial- and hedgehog-targeted agent. In addition, its portfolio comprises various research-stage candidates. The company s DNA therapeutics are being developed in partnership with Intrexon Corporation through a synthetic biology platform that allows for targeted, controlled production of therapies in humans with a biologic on/off switch. ZIOPHARM Oncology, Inc. was founded in 2003 and is headquartered in New York, New York with operations center located in Boston, Massachusetts.

ZIOPHARM Oncology, Inc.

1180 Avenue of the Americas 20th Floor

New York, NY 10036

Phone: 646-214-0700 Fax: 646-214-0711

Website: http://www.ziopharm.com

News:

seekingalpha.com/article/1899291-ziopharm-finally-a-winner-in-the-war-on-cancer?

ZNGA @ $4.00

Hold

Take no action

There is no good option interest at this time.

History:

Cost basis $14.00 per share. Premiums collected: $2.05 per share 14.64% Return in 22 months

$10,000 would have generated $1464.00

actual trades:

03/19/2012 Sell To Open ZNGA Apr12 16 Call $0.20 03/18/2012 Buy To Close EXPIRED ZNGA MAR12 15 CALL 02/21/2012 Sell To Open ZNGA Mar12 15 Call $0.40 02/17/2012 Buy ZNGA – Option Assignment $14.00 02/17/2012 Buy To Close ZNGA Feb12 14 Put 02/06/2012 Sell To Open ZNGA Feb12 14 Put$1.55

Zynga Inc. develops, markets, and operates online social games as live services on the Internet, social networking sites, and mobile platforms. The company offers its online social games under the CityVille, Zynga Poker, FarmVille, CastleVille, FrontierVille, Mafia Wars, Word with Friends, Hidden Chronicles, Zynga Bingo, Scramble With Friends, Slingo, and Dream Heights names. Its games are available on various platforms, including Facebook and other social networks, as well as mobile platforms, such as Apple iOS and Google Android worldwide. The company was formerly known as Zynga Game Network Inc. and changed its name to Zynga Inc. in November 2010. Zynga Inc. was founded in 2007 and is headquartered in San Francisco, California.

Zynga, Inc.

699 Eighth Street

San Francisco, CA 94103 Phone: 855-449-9642 Fax: 302-636-5454

Website: http://www.zynga.com

News:

Quote of the Month:

““It is not necessary to do extraordinary things to get extraordinary results”

~ Warren Buffet

Until Next Time

Brad Lee

The Options Oracle

https://theoptionsoracle.com/

The place for safer Investments

Established 23 February 2009
Ask The Oracle
Webinar Sunday 8 pmESTto
explain this newsletter, or other questions
you might have.
Here is the link
https://secure.join.me/BradLeeOptions
There is no preregistration.
Please use the phone option for audio
Summary of Trades:
Cash Covered Puts
Sell To Open SCTY Jan 2014 $55 Put @
Market
Sell To Open QCOR Jan 2014 $50 Put @
Market
Stock Covered Calls
(do not buy into this position)
Sell To Open MYGN January $27 Call @
Market
Sell To Open VJET Feb 2014 $60 Call @
Market
Sell To Open CLSN Jan 2014 $4 Call @
Market
Sell To Open PRKR March 2014 $6 Call @
market
*Sell To Open SCTY Jan 2014 $60 Call @
Market
Called away:
Nothing Called away
Past performance click here

https://theoptionsoracle.com/past-performances/

Company News

New toll free number: 1-866-466-4617

Feel free to contact me personally!

Got a question or concern? Want to learn my philosophy and why it pays so well and consistently? Go to

“contact us” https://theoptionsoracle.com/contacting-us/

and schedule a consultation.

Military discounts are here!

Thank you for your service!

Refer a Friend

The greatest compliment you can give me is to share me with your friends.

Disclosure: These are my actual trades.

I am not telling you what to do, I am showing you what I am doing.

Your subscription fee may be 100% TAX DEDUCTIBLE if used for educational business/investment purposes. Check withyour Licensed Professional adviser

In Loving Memory
Ronald E. Lee 1939-2013

Company News
Auto Trading is now active!

Don’t want to be bothered doing the trades?
Auto-trading is for you. Your account will
automatically do whatever I do.
You are still in control, you set the limits
either a dollar amount or a percentage.
Go to the main site, the Auto-trade link is on
the site

https://theoptionsoracle.com/auto-trading/
We will be doing a webinar Sunday 8 pm est to explain this newsletter.

Here is the link

https://secure.join.me/BradLeeOptions

Disclosure: These are my actual trades.

Your subscription fee may be 100% TAX DEDUCTIBLE if used for educational business/investment purposes. Check with your Licensed Professional adviser

Options involve risk and are not suitable for all
investors. Prior to trading options, you must be
approved for options trading and read the
Characteristics and Risks of Standardized

Copies of this document may also be obtained from your broker, from any exchange on which options are traded, by placing an order online, or by contacting the Options Clearing Corporation directly at 1 N. Wacker Dr., Suite 500, Chicago, IL 60606. (1-888-678-4667).

Brad Lee AKA “The Options Oracle” and “The Money Medic” is an individual investor who does not manage money for any financial institution. You are purchasing the list of stocks that he uses to select options contracts he feels will return him the highest, safest profits. Brad is not a broker, or financial adviser. He is a remarkable investor who has developed a successful strategy for himself, and is willing to share some of his magic with you. We urge you to paper trade these picks and learn how to develop a strategy that is appropriate for you. Thank You.

We make no recommendations on investment and we do not provide financial, tax or legal advice. Content and tools are provided for educational and informational purposes only.

Disclaimer

Trading or investment in stocks, futures & options, and commodity are subject to potential market risks. You can use our materials or recommendations for educational purposes, this is not intended as Trading or Investment advice. We are not financial advisers. We cannot provide any advice as to whether or not options or our trading ideas are suitable investments for your particular financial situation. We are in the business of publishing our trade ideas for market analysis only. We highly recommend that our subscribers review their trading allocation with a qualified registered financial adviser/planner.

Legal Disclaimer: we do not exist to render and do not give legal, tax, economic or investment advice and disclaims all liability for the actions or inaction taken or not as a result of communications from or to its members, officers, directors, employees and contractors. Each individual should consult his/her own counsel, accountant and other advisors as to legal, tax, economic, investment and related matters concerning any type of investments.

This email and any files transmitted with it are solely intended for the use of the addressee(s) and may contain information that is confidential and privileged. If you receive this email in error, please advise us by return email immediately. Please also disregard the contents of the email, delete it and destroy any copies immediately.